FDC Ltd.
Snapshot View

249.25 +2.10 ▲0.9%

20 May 2022, 04:01:00 PM
Volume: 5,291

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.fdcindia.com
Market Cap 4,207.59 Cr.
Enterprise Value(EV) 4,182.60 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) 14.98 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) 16.64 Trailing Twelve Months Ending 2021-12
Industry PE 29.26 Trailing Twelve Months Ending 2021-12
Book Value / Share 114.92 Trailing Twelve Months Ending 2021-12
Price to Book Value 2.17 Calculated using Price: 249.25
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 16.88 Cr. 168,810,084 Shares
FaceValue 1
Company Profile

FDC make modest beginning in 1936, with marketing of vitamins and a range of prescription formulations. FDC set up its first formulations manufacturing facility in 1949. Subsequently, in 1963, FDC pioneered the manufacture of specialized ophthalmic formulations in India. FDC was the first organization to introduce the BFS (Blow-Fill-Seal) technology for ophthalmic in South East Asia. In 1972, FDC initiated the concept of Oral Rehydration Salts (ORS). Today its pioneer brand ‘Electral’ stands apart with a special identity- an impressive achievement in a fiercely competitive market. FDC’s API plant at Roha (Maharashtra) was among the first few API facilities in India to get US-FDA approval in 1984. Since then, FDC has to its credit a number of new molecules, introduced for the first time in the nation.

Today, FDC carries forward the flaming spirit of its first dream, achieving accreditations from the US-FDA, UK-MHRA, MCC-RSA, and the UAE, to cite a few. FDC is a forerunner in manufacturing and marketing of Oral Rehydration Salts (ORS) and Ophthalmics. FDC has also set-up globally approved, multi-location manufacturing facilities for Active Pharmaceuticals Ingredients (APIs) as well as Finished Dosage Forms. These facilities are located at Roha, Waluj and Sinnar in Maharashtra, Verna in Goa and Baddi in Himachal Pradesh. FDC markets hundreds of products in India and exports many of these to various countries.

Business area of the company

FDC Limited is among India’s leading fully integrated pharmaceutical companies. The Company is a pioneer in the manufacture of specialised formulations, and among the world’s foremost manufacturers and marketers of Oral Rehydration Salts (ORS). Over its long history of 85 years, the Company has maintained a distinguished reputation for high-quality, affordable products and built a market-leading brand portfolio.

Products

Formulations

FDC is a pioneer in the manufacture of specialized formulations, and the world's leading manufacturer of ORS (Oral Rehydration Salts) since 1972. It is a fully-integrated Pharmaceutical Company, with US-FDA and UK-MHRA approved API and formulations manufacturing facilities. FDC was the first in South East Asia to offer ophthalmic formulations, using Blow-Fill-Seal (BFS) technology.

It has its presence in numerous therapeutic segments: anti-infectives, gastrointestinals, ophthalmologicals, vitamins/ minerals/ dietary supplements, cardiac, anti-diabetes, respiratory, gynaecology, dermatology, analgesics and others. FDC’s Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm are leading brands in their respective segments in India.

Functional Food

Products that deliver benefits consistently are the hallmark of FDC's Food Division. These products have quality certifications such as BIS (ISI mark) and HACCP. FDC has a wide range of functional foods and beverages.

Few well known brands and their use/categories are: Prosoyal for lactose intolerance; Humyl as an ideal protein supplement; Zefrich as a complete family nourisher; Enerzal, a Balanced Energy drink; and Simyl MCT, Simyl LBW and MumMum 1 and 2 as infant milk substitutes.

API

To develop cost-effective, environment-friendly, high-quality APIs meeting stringent ICH standards is the main focus of FDC’s API division. The company’s products and manufacturing facilities have been inspected and approved multiple times by major Regulatory bodies such as US-FDA and WHO-GMP. Till date the company has developed over twenty-three APIs of which fourteen have already been commercialized and exported across the world.

Milestones

  • 1936: Mr. Anand Chandavarkar set-up Fairdeal Corporation (FDC) to import drugs, infant foods and surgical appliances for distribution in India
  • 1940: The Fairdeal Corporation was incorporated as a Fairdeal Corporation (Private) Limited Company under Indian Companies Act, 1913
  • 1949: Formulation plant established in Jogeshwari, Mumbai
  • 1963: Introduced Vanmycetin Eye Drops - starting point for ophthalmic and ENT range
  • 1972: Introduced Electral - a result of pioneering work in Oral Rehydration Therapy
  • 1974: Fairdeal's R&D facilities obtain recognition from Government of India
  • 1977: Active Pharmaceutical Ingredient (API) plant commissioned at Roha, Maharashtra
  • 1984: Foods division set up for manufacture of specialized infant foods at Roha
  • 1985: First US FDA approval of API plant at Roha
  • 1986: Fairdeal Corporation (Pvt.) Ltd. was renamed FDC Private Limited
  • 1987: Multi-purpose formulation plant commissioned at Waluj in Maharashtra
  • 1989: Started commercial production of Flurbiprofen
  • 1991: Biotechnology research centre set-up at Waluj
  • 1991: Production of Timolol Maleate (API) started
  • 1992: National Award from the Council of Scientific Research and Industry (CSRI) for Indigenous R&D of Flurbiprofen and Timolol Maleate
  • 1994: First Indian company to introduce BFS (Blow-Fill-Seal) technology in Ophthalmics, which optimizes sterility and is highly user friendly
  • 1996: Public issue of 26,28,200 equity shares of Rs. 10 each at a premium of Rs. 90 each
  • 1996: FDC awarded 'Export House' status
  • 1996: Specialized & dedicated field force established to promote ophthalmic specialties
  • 1998: UK-MHRA approval for ophthalmic facility at Waluj
  • 1999: FDC International set-up in the UK for distribution and marketing of Ophthalmic products
  • 2002: First UK-MHRA approval for oral solids facility at Goa Plant - I
  • 2004: FDC South Africa established
  • 2005: First US-FDA approval for ophthalmic facility at Waluj
  • 2005: 2 ANDAs filed for ophthalmic dosage forms in the U.S.
  • 2006: Forbes rates FDC among the 'BEST UNDER A BILLION COMPANIES'
  • 2006: US Patent awarded for UV-Lube, the first definitive therapy for dry-eye syndrome
  • 2008: US-ANDA approval received for three ophthalmic formulations
  • 2008: US-FDA approval received for Waluj
  • 2008: MHRA approval received for Goa unit - I
  • 2008: New oral Cephalosporins facility set-up at Baddi
  • 2009: UK-MHRA approval received for Goa units - I, II & III
  • 2011: Pharmexcil CERTIFICATE OF APPRECIATION PATENT AWARD 2010-2011, in recognition of commendable contribution in Bulk Drugs Category
  • 2012: UK-MHRA renewal received for Goa Plants - I, II & III
  • 2012: US-FDA renewal received for Waluj
  • 2012: Pharmexcil CERTIFICATE OF APPRECIATION PATENT AWARD 2011-2012, in recognition of commendable contribution in Bulk Drugs Category
  • 2013: UK-MHRA renewal received for Waluj
  • 2013: US-FDA renewal received for Roha
  • 2013: IDMA Margi Memorial Best Patent Award for “BEST NEW CHEMICAL ENTITY PATENT AWARD 2012-13”
  • 2013: Pharmexcil Patent Award “NEW CHEMICAL ENTITIES (NCEs) – SILVER AWARD 2012-2013”
  • 2014: US-FDA renewal received for Waluj
  • 2014: PICS approval received for Waluj
  • 2016: US-FDA approval received for Baddi
  • 2016: Pharmexcil Patent Award “NEW CHEMICAL ENTITIES (NCEs) – SILVER AWARD 2015-2016”.
  • 2017-18: The company has launched the Enerzal 500 ml in pet bottle as well as 1 Litre in Tetrapak with Orange and Apple flavor.
  • 2018-19: The company received the Abbreviated New Drug Application (ANDA) Approval for Dorzolamide 2% Ophthalmic Solution 5 ml & 10 ml.
  • 2019-20: FDC receives GMP certificate from UK MHRA for Goa unit.
  • 2020: FDC has launched new strength variants of its Favipiravir brands - PiFLU and Favenza, used to treat mild to moderate cases of COVID-19 in India.
  • 2020: FDC inks pact to acquire additional stake in FDC SA.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.85%
1 Week
+1.67%
1 Month
-10.85%
3 Month
-15.62%
6 Month
-11.54%
1 Year
-26.46%
2 Year
+6.43%
5 Year
+38.28%
10 Year
+226.46%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 21.01 16.63 16.64 16.76 16.02 13.67 12.63 16.10 18.36
Return on Capital Employed (%) 26.85 27.12 23.02 23.15 21.51 19.04 17.64 21.63 23.74
Return on Assets (%) 16.92 13.26 13.34 14.01 12.00 9.05 8.30 10.48 11.85

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 784 845 936 1,082 1,270 1,276 1,445 1,547 1,734 1,908
Non Curr. Liab. 31 31 24 20 217 211 229 315 299 17
Curr. Liab. 154 196 188 163 389 480 497 565 622 298
Minority Int. 0 0
Equity & Liab. 970 1,072 1,148 1,266 1,876 1,968 2,172 2,427 2,655 2,223
Non Curr. Assets 558 619 646 742 958 977 1,113 1,181 1,303 1,155
Curr. Assets 411 452 502 523 918 991 1,058 1,245 1,352 1,068
Misc. Exp. not W/O 1 0
Total Assets 970 1,072 1,148 1,266 1,876 1,968 2,172 2,427 2,655 2,223

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 773 846 889 994 1,014 1,075 1,091 1,344 1,333 1,500
Other Income 46 42 46 39 50 51 43 69 97 81
Total Income 819 888 935 1,033 1,064 1,126 1,134 1,413 1,430 1,582
Total Expenditure -592 -641 -691 -766 -770 -848 -860 -1,051 -999 -1,214
PBIDT 227 246 244 268 294 278 274 362 431 367
Interest -2 -3 -2 -1 -1 -1 -1 -3 -3 -3
Depreciation -28 -25 -39 -34 -35 -35 -33 -37 -38 -38
Taxation -43 -83 -56 -63 -63 -67 -67 -80 -87 -72
Exceptional Items -6 -1 -2 -2
PAT 155 135 148 169 188 174 172 241 301 253
Minority Interest 0 0
Share Associate 0 0 0 -2 -1 0
Other Related Items
Consolidated Net Profit 155 135 148 169 189 174 170 240 301 253
Adjusted EPS 9 8 8 9 11 10 10 14 18 15

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 144 150 150 128 174 154 150 112 250 207
Cash Fr. Inv. -108 -107 -55 -89 -73 -144 20 -120 -98 -77
Cash Fr. Finan. -58 -63 -75 -48 -97 0 -169 0 -142 -129
Net Change -22 -20 19 -9 4 11 1 -8 10 1
Cash & Cash Eqvt 24 4 23 15 16 27 28 20 30 30

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 69.24 69.24 69.24 69.35 69.35 69.35 69.35 69.36 69.36
Public 30.76 30.76 30.76 30.65 30.65 30.65 30.65 30.64 30.64
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 16 May 2022
Corporate Action-Updates on Buy back
Completion of Extinguishment/destruction of a total of 29 00 000 Equity Shares of the face value of Rs. 1 each.
Fri, 13 May 2022
Board Meeting Intimation for Audited Financial Results Of The Company For The Quarter And Financial Year Ended March 31 2022.
FDC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2022 inter alia to consider and approve This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday May 25 2022 at Mumbai to interalia consider and approve the Audited Financial Results of the Company for the quarter and Financial Year ended March 31 2022.Further in accordance with Code of Conduct adopted by the Company SEBI (Prohibition of Insider Trading) (Amendment) Regulations 2018 and vide our intimation letter dated March 28 2022 the Trading Window of the Company has been closed for all the Directors and Designated Persons from Friday April 01 2022 till 48 hours after the declaration of Audited Financial Results for the quarter and year ended March 31 2022.
Tue, 10 May 2022
Announcement under Regulation 30 (LODR)-Public Announcement-Buyback of Shares
Post Offer Public Announcement in terms of Regulation 24(vi) of the Securities and Exchange Board of India (Buyback of Securities) Regulations 2018 in respect to the Buyback offer of 29 00 000 equity shares by FDC Limited

Technical Scans View Details

Fri, 20 May 2022
Closing Above Previous High Closing Above Previous High
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
High Decrease 1 Month High Decrease 1 Month
High Decrease 3 Months High Decrease 3 Months
MFI Below 20 MFI Below 20

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,659.12 915.50 +3.5%
Divi's Laboratories Ltd. 114,020.08 4,295.05 +2.2%
Cipla Ltd. 78,954.82 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. 70,669.41 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. 52,783.35 3,671.00 +1.0%
Gland Pharma Ltd. 50,388.39 3,061.70 -1.1%
Piramal Enterprises Ltd. 45,754.22 1,917.10 +1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.09 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 44.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 31.37 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.38 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.57 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 41.59 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 36.83 1,917.10 +1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 10.53 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 3.79 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.68 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.54 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 7.04 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 1.29 1,917.10 +1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 0.10 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,917.10 +1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,917.10 +1.2%